Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Immunext Inc.
Headquarters: Lebanon, NH, United States of America
Website: http://www.immunext.com
Year Founded: 2011
Status: Private
BioCentury | Aug 21, 2021
Targets & Mechanisms
Next-generation multiple sclerosis therapies look beyond B cells
Early-stage approaches aim for more precise immune suppression, remyelination
BioCentury | Oct 19, 2019
Product Development
Tracking the rise and fall of next-generation checkpoint targets for cancer
BioCentury’s analysis of next-generation checkpoint targets finds three that are gathering steam
BioCentury | Aug 24, 2018
Targets & Mechanisms
Computing checkpoints
Compugen takes the plunge into clinical development with a mAb against a new checkpoint
BioCentury | May 14, 2015
Distillery Therapeutics
Therapeutics: V-region immunoglobulin-containing suppressor of T cell activation (VISTA); programmed cell death 1 (PD-1; PDCD1; CD279); programmed cell death 1
BioCentury | Nov 5, 2012
Emerging Company Profile
ImmuNext: New VISTAs
ImmuNext developing VISTA antagonists, agonists for cancer, autoimmune diseases
Items per page:
1 - 10 of 10